Low RBC counts predict high on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention and treated with clopidogrel

References

[1] Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence[J]. J Am Coll Cardiol, 2005, 45(8): 1157-1164. doi: 10.1016/j.jacc.2005.01.034

[2] Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J]. JAMA, 2009, 302(8): 849-857. doi: 10.1001/jama.2009.1232

[3] Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y₁₂ receptor inhibitor treatment in percutaneous coronary intervention[J]. JACC Cardiovasc Interv, 2019, 12(16): 1521-1537. doi: 10.1016/j.jcin.2019.03.034

[4] Karolczak K, Soltysik B, Kostka T, et al. Platelet and red blood cell counts, as well as the concentrations of uric acid, but not homocysteinaemia or oxidative stress, contribute mostly to platelet reactivity in older adults[J]. Oxid Med Cell Longev, 2019, 2019: 9467562. doi: 10.1155/2019/9467562

[5] Heptinstall S, Johnson A, Glenn JR, et al. Adenine nucleotide metabolism in human blood-important roles for leukocytes and erythrocytes[J]. J Thromb Haemost, 2005, 3(10): 2331-2339. doi: 10.1111/j.1538-7836.2005.01489.x

[6] Wernly B, Erlinge D, Pernow J, et al. Ticagrelor: a cardiometabolic drug targeting erythrocyte-mediated purinergic signaling?[J]. Am J Physiol Heart Circ Physiol, 2021, 320(1): H90-H94. doi: 10.1152/ajpheart.00570.2020

[7] Stafford NP, Pink AE, White AE, et al. Mechanisms involved in adenosine triphosphate-induced platelet aggregation in whole blood[J]. Arterioscler Thromb Vasc Biol, 2003, 23(10): 1928-1933. doi: 10.1161/01.ATV.0000089330.88461.D6

[8] Neubauer H, Günesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study[J]. Eur Heart J, 2003, 24(19): 1744-1749. doi: 10.1016/S0195-668X(03)00442-1

[9] Gremmel T, Steiner S, Seidinger D, et al. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation[J]. Transl Res, 2013, 161(5): 421-429. doi: 10.1016/j.trsl.2012.12.015

[10] Akinosoglou K, Perperis A, Theodoraki S, et al. Sepsis favors high-on-clopidogrel platelet reactivity[J]. Platelets, 2018, 29(1): 76-78. doi: 10.1080/09537104.2017.1319919